Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $65

Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $50 to $65.